# Final Rule: Requirements for Child-Resistant Packaging; Packages Containing 250 mg or More of Naproxen
> **US Consumer Product Safety Commission** · Final rule. · Published 1995-07-28 · Effective 1996-02-06 · 60 FR 38671
## Document
- **Document number:** 95-18504
- **Category:** final-rule
- **Agency:** US Consumer Product Safety Commission
- **Federal Register citation:** 60 FR 38671
- **CFR reference:** 16 CFR 1700
- **Publication date:** 1995-07-28
- **Effective date:** 1996-02-06
## Abstract

The Commission is issuing a rule to require child-resistant packaging for naproxen preparations containing 250 mg or more of naproxen per retail package. Naproxen is marketed as an anti- inflammatory drug. It is used to treat various forms of arthritis, mild to moderate pain, and menstrual pain. The Commission has determined that child-resistant packaging is necessary to protect children under 5 years of age from serious personal injury and serious illness resulting from ingesting naproxen. The Commission takes this action under the authority of the Poison Prevention Packaging Act of 1970.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/1995/07/28/95-18504/final-rule-requirements-for-child-resistant-packaging-packages-containing-250-mg-or-more-of-naproxen)
---
*AI Analytics · CC0 1.0*